An immunotherapy for neuroblastoma, a cancer of the nervous system that strikes young children, works by flagging tumor cells for the immune system to destroy. Penn State College of Medicine researchers found that blocking a protein called VPS34 causes tumor cells to display more of the molecule that flag attaches to, making them easier for immune cells to find and kill. Read more: https://medicalxpress.com/news/2026-10-pediatric-cancer-visible-boosts-immunotherapy.html

A new scientific breakthrough may soon mean hope for children and families facing one of pediatric cancer’s deadliest foes. Instead of targeting viruses or bacteria, this new mRNA vaccine is setting its sights on an aggressive childhood tumor: neuroblastoma. Read more: https://www.futura-sciences.com/en/a-childhood-cancer-faces-a-new-enemy-this-mrna-vaccine-isnt-for-viruses_36759/

A new study from RCSI University of Medicine and Health Sciences demonstrates a novel approach in anticancer vaccine development. The results, published in Molecular Therapy Oncology, present the first preclinical evidence showing the efficacy of an mRNA vaccine in targeting neuroblastoma, the deadliest childhood cancer. Read more: https://medicalxpress.com/news/2026-06-anticancer-vaccine-early-success-neuroblastoma.html

A Children’s Hospital Los Angeles study has shed new light on the molecular drivers of FOXR2-activated CNS neuroblastoma, an extremely rare pediatric brain tumor that can be difficult to diagnose without advanced testing. Read more: https://www.newswise.com/articles/children-s-hospital-los-angeles-researchers-uncover-genetic-clues-to-rare-childhood-brain-tumor

Following induction treatment for high-risk neuroblastoma, more than half of children experience cisplatin-induced hearing loss (CIHL), according to research published in JCO Clinical Advances. Read more: https://www.cancertherapyadvisor.com/news/cisplatin-hearing-loss-pediatric-high-risk-neuroblastoma/

Researchers investigating neuroblastoma – a cancer that primarily affects babies and children under five – have discovered that tetracaine, a long‑established local anaesthetic, can significantly suppress the cancer cells’ ability to invade surrounding tissue in laboratory experiments. Read more: https://www.icr.ac.uk/about-us/icr-news/detail/local-anaesthetic-shows-promise-in-blocking-childhood-cancer-spread--study-finds

Researchers at Linköping University show how two important cancer-related proteins can be prevented from collaborating with each other. The discovery shows the way toward future medications to combat, for example, neuroblastoma in children. Read more: https://medicalxpress.com/news/2026-04-scientists-undruggable-childhood-cancer-protein.html

The University of Queensland researchers used cutting-edge technology to map the biology of neuroblastoma—a cancer that typically develops in children under the age of 5—finding a hidden "shield" the tumors use as protection. Certain immune cells surrounding the tumor were also discovered to act as "bodyguards" for the cancer. Read more here: https://medicalxpress.com/news/2026-03-shields-bodyguards-scientists-uncover-hidden.html

Survival outcomes are comparable or better with proton beam therapy (PBT) compared with photon radiotherapy (XRT) in pediatric patients with neuroblastomas, according to findings published in Cancer Medicine . Read more: https://www.cancertherapyadvisor.com/news/proton-beam-therapy-photon-radiotherapy-pediatric-neuroblastoma/

Researchers have shown that subtle mutational differences in a gene called ATRX help explain why children with the same type of neuroblastoma respond differently to treatment. Read more: https://www.icr.ac.uk/about-us/icr-news/detail/new-research-reveals-how-subtle-genetic-differences-shape-neuroblastoma-behaviour